Serotonin function in panic disorder: Important, but why?

Neuropsychopharmacology

Volumn 31, Issue 1, 2006, Pages 1-11

  Maron, Eduard ^a   Shlik, Jakov ^b  

^a UNIVERSITY OF TARTU   (Estonia)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Brain imaging; Genetic polymorphism; Panic disorder; Serotonin

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BUSPIRONE; DEXFENFLURAMINE; IPSAPIRONE; MONOAMINE OXIDASE INHIBITOR; ONDANSETRON; PAROXETINE; RITANSERIN; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE;

ANXIETY DISORDER; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG EFFECT; GENERALIZED ANXIETY DISORDER; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MENTAL PATIENT; NEUROBIOLOGY; NEUROIMAGING; NEUROTRANSMISSION; PANIC; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEROTONINERGIC SYSTEM; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

ANIMALS; BRAIN; HUMANS; MONOAMINE OXIDASE; PANIC DISORDER; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 32844465837     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300880     Document Type: Review

References (114)

1. Barnes NM, Sharp T (1999). A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083-1152.
2. Bell C, Abrams J, Nutt DJ (2001). Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 178: 399-405.
3. Bell C, Forshall S, Adrover M, Nash J, Hood S, Argyropoulos S et al (2002). Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol 16: 5-14.
4. Bell CJ, Nutt DJ (1998). Serotonin and panic. Br J Psychiatry 172: 465-471.
5. 2-induced anxiety in healthy volunteers with the serotonin antagonist metergoline. Am J Psychiatry 156: 1635-1637.
6. Bertani A, Perna G, Arancio C, Caldirola D, Bellodi L (1997). Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol 17: 97-101.
7. Bressa GM, Marini S, Gregori S (1987). Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam. Int J Clin Pharmacol Res 7: 111-119.
8. Broocks A, Bandelow B, George A, Jestrabeck C, Opitz M, Bartmann U et al (2000). Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int Clin Psychopharmacol 15: 153-161.
9. Broocks A, Meyer T, Opitz M, Bartmann U, Hillmer-Vogel U, George A et al (2003). 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. Eur Neuropsychopharmacol 13: 153-164.
10. Carli M, Afkhami-Dastjerdian S, Reader TA (1996). [3H]8-OH-DPAT binding and serotonin content in rat cerebral cortex after acute fluoxetine, desipramine, or pargyline. J Psychiatry Neurosci 21: 114-122.
11. Charig EM, Anderson IM, Robinson JM, Nutt DJ, Cowen PJ (1986). L-typtophan and prolactin release: evidence for interaction between 5HT1 and 5HT2 receptors. Hum Psychopharmacol 1: 93-97.
12. Charney DS, Heninger GR (1986). Serotonin function in panic disorders. The effect of intravenous tryptophan in healthy subjects and patients with panic disorder before and during alprazolam treatment. Arch Gen Psychiatry 43: 1059-1065.
13. Charney DS, Woods SW, Goodman WK, Heninger GR (1987). Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacologia 92: 14-24.
14. Coplan JD, Gorman JM, Klein DF (1992). Serotonin related functions in panic-anxiety: a critical overview. Neuropsychopharmacology 6: 189-200.
15. Coplan JD, Lydiard RB (1998). Brain circuits in panic disorder. Biol Psychiatry 44: 1264-1276.
16. Cutler NR, Keppel Hesselink JM, Sramek JJ (1994). A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry 18: 447-463.
17. Deakin JFW (1996). 5-HT, antidepressant drugs and the psychosocial origins of depression. J Psychopharmacol 10: 31-38.
18. Deakin JFW, Graeff F (1991). 5-HT and mechanisms of defence. J Psychopharmacol 5: 305-315.
19. den Boer JA, Westenberg HG (1990a). Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder. Psychiatry Res 31: 267-278.
20. den Boer JA, Westenberg HG (1990b). Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacologia 102: 85-94.
21. Deckert J, Catalano M, Heils A, Di Bella D, Friess F, Politi E et al (1997). Functional promoter polymorphism of the human serotonin transporter: lack of association with panic disorder. Psychiatr Genet 7: 45-47.
22. Deckert J, Catalano M, Syagailo YV, Bosi M, Okladnova O, Di Bella D et al (1999). Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet 8: 621-624.
23. Deckert J, Meyer J, Catalano M, Bosi M, Sand P, DiBella D et al (2000). Novel 5′-regulatory region polymorphisms of the 5-HT2C receptor gene: association study with panic disorder. Int J Neuropsychopharmacol 3: 321-325.
24. Depot M, Caille G, Mukherjee J, Katzman MA, Cadieux A, Bradwejn J (1999). Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Neuropsychopharmacology 20: 177-187.
25. Dreshfield-Ahmad LJ, Thompson DC, Schaus JM, Wong DT (2000). Enhancement in extracellular serotonin levels by 5-hydroxytryptophan loading after administration of WAY 100635 and fluoxetine. Life Sci 66: 2035-2041.
26. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ et al (1999). PET imaging of serotonin IA receptor binding in depression. Biol Psychiatry 46: 1375-1387.
27. Fehr C, Grintschuk N, Szegedi A, Anghelescu I, Klawe C, Singer P et al (2000a). The HTR1B 861G > C receptor polymorphism among patients suffering from alcoholism, major depression, anxiety disorders and narcolepsy. Psychiatry Res 97: 1-10.
28. Fehr C, Schleicher A, Szegedi A, Anghelescu I, Klawe C, Hiemke C et al (2001). Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy. Prog Neuropsychopharmacol Biol Psychiatry 25: 965-982.
29. Fehr C, Szegedi A, Anghelescu I, Klawe C, Hiemke C, Dahmen N (2000b). Sex differences in allelic frequencies of the 5-HT2C Cys23Ser polymorphism in psychiatric patients and healthy volunteers: findings from an association study. Psychiatr Genet 10: 59-65.
30. Fickbohm DJ, Katz PS (2000). Paradoxical actions of the serotonin precursor 5-hydroxytryptophan on the activity of identified serotonergic neurons in a simple motor circuit. J Neurosci 20: 1622-1634.
31. Frazer A, Hensler JG (1990). 5-HT1A receptors and 5-HT1A-mediated responses: effect of treatments that modify serotonergic neurotransmission. Ann N Y Acad Sci 600: 460-474.
32. Germine M, Goddard AW, Sholomskas DE, Woods SW, Charney DS, Heninger GR (1994). Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res 54: 115-133.
33. Gingrich J, Goldman D, Mann JJ, Hariri A (2004). Novel serotonin transporter gene promoter variants and psychiatric illness. Neuropsychopharmacology 29(Suppl 1): 45-46.
34. Goddard AW, Charney DS (1997). Toward an integrated neurobiology of panic disorder. J Clin Psychiatry 58: 4-11.
35. Goddard AW, Sholomskas DE, Walton KE, Augeri FM, Charney DS, Heninger GR et al (1994). Effects of tryptophan depletion in panic disorder. Biol Psychiatry 36: 775-777.
36. Gorman JM, Kent JM, Sullivan GM, Coplan JD (2000). Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157: 493-505.
37. Gottesman II, Gould TD (2003). The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160: 636-645.
38. Graeff FG (1997). Serotonergic systems. Psychiatr Clin North Am 20: 723-739.
39. Gross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L et al (2002). Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416: 396-400.
40. Grove G, Coplan JD, Hollander E (1997). The neuroanatomy of 5-HT dysregulation and panic disorder. J Neuropsychiatry Clin Neurosci 9: 198-207.
41. Hamilton SP, Heiman GA, Haghighi F, Mick S, Klein DF, Hodge SE et al (1999). Lack of genetic linkage or association between a functional serotonin transporter polymorphism and panic disorder. Psychiatr Genet 9: 1-6.
42. Hamilton SP, Slager SL, Heiman GA, Haghighi F, Klein DF, Hodge SE et al (2000). No genetic linkage or association between a functional promoter polymorphism in the monoamine oxidase-A gene and panic disorder. Mol Psychiatry 5: 465-466.
43. Han L, Nielsen DA, Rosenthal NE, Jefferson K, Kaye W, Murphy D et al (1999). No coding variant of the tryptophan hydroxylase gene detected in seasonal affective disorder, obsessive-compulsive disorder, anorexia nervosa, and alcoholism. Biol Psychiatry 45: 615-619.
44. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D et al (2002). Serotonin transporter genetic variation and the response of the human amygdala. Science 297: 400-403.
45. Hensler JG, Kovachich GB, Frazer A (1991). A quantitative autoradiographic study of serotonin1A receptor regulation. Effect of 5,7-dihydroxytryptamine and antidepressant treatments. Neuropsychopharmacology 4: 131-144.
46. Hollander E, Liebowitz MR, DeCaria C, Klein DF (1990). Fenfluramine, cortisol, and anxiety. Psychiatry Res 31: 211-213.
47. Huang YY, Battistuzzi C, Oquendo MA, Harkavy-Friedman J, Greenhill L, Zalsman G et al (2004). Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. Int J Neuropsychopharmacol 7: 441-451.
48. Inada Y, Yoneda H, Koh J, Sakai J, Himei A, Kinoshita Y et al (2003). Positive association between panic disorder and polymorphism of the serotonin 2A receptor gene. Psychiatry Res 118: 25-31.
49. Ishiguro H, Arinami T, Yamada K, Otsuka Y, Toru M, Shibuya H (1997). An association study between a transcriptional polymorphism in the serotonin transporter gene and panic disorder in a Japanese population. Psychiatry Clin Neurosci 51: 333-335.
50. Iversen SD (1984). 5-HT and anxiety. Neuropharmacology 23: 1553-1560.
51. Jacobs BL, Azmitia EC (1992). Structure and function of the brain serotonin system. Physiol Rev 72: 165-229.
52. Kahn RS, Asnis GM, Wetzler S, van Praag HM (1988a). Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacologia 96: 360-364.
53. Kahn RS, Westenberg HG (1985). L-5-hydroxytryptophan in the treatment of anxiety disorders. J Affect Disord 8: 197-200.
54. Kahn RS, Westenberg HG, Verhoeven WM, Gispen-de Wied CC, Kamerbeek WD (1987). Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol 2: 33-45.
55. Kahn R, Wetzler S, Asnis GM, Kling MA, Suckow RF, van Praag HM (1991). Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects. Psychiatry Res 37: 25-34.
56. Kahn R, Wetzler S, van Praag HM, Asnis GM, Strauman T (1988b). Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res 25: 101-104.
57. Kent JM, Coplan JD, Gorman JM (1998). Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry 44: 812-824.
58. Kent JM, Coplan JD, Martinez J, Karmally W, Papp LA, Gorman JM (1996). Ventilatory effects of tryptophan depletion in panic disorder: a preliminary report. Psychiatry Res 64: 83-90.
59. Klaassen T, Klumperbeek J, Deutz NE, van Praag HM, Griez E (1998). Effects of tryptophan depletion on anxiety and on panic provoked by carbon dioxide challenge. Psychiatry Res 77: 167-174.
60. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW (1991). Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biol Psychiatry 30: 973-984.
61. Koszycki D, Zacharko RM, Le Melledo JM, Young SN, Bradwejn J (1996). Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol Psychiatry 40: 648-655.
62. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD et al (2003). Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 23: 8788-8799.
63. Lerer B, Macciardi F, Segman RH, Adolfsson R, Blackwood D, Blairy S et al (2001). Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Mol Psychiatry 6: 579-585.
64. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S et al (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531.
65. Lesch KP, Gutknecht L (2004). Focus on the 5-HT1A receptor: emerging role of a gene regulatory variant in psychopathology and pharmacogenetics. Int J Neuropsychopharmacol 7: 381-385.
66. Lucki I (1998). The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44: 151-162.
67. Marek GJ, McDougle CJ, Price LH, Seiden LS (1992). A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacologia 109: 2-11.
68. Maron E, Kuikka JT, Shlik J, Vasar V, Vanninen E, Tiihonen J (2004a). Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Res 132: 173-181.
69. Maron E, Lang A, Tasa G, Liivlaid L, Tõru I, Must A et al (2005a). Associations between serotonin-related gene polymorphisms and panic disorder. Int J Neuropsychopharmacol 8: 261-266.
70. Maron E, Nikopensius T, Kõks S, Altmäe S, Heinaste E, Vabrit K et al (2005b). Association study of 90 candidate genetic polymorphisms in panic disorder. Psychiatr Genet 15: 17-24.
71. Maron E, Tasa G, Tõru I, Lang A, Vasar V, Shlik J (2004b). Association between serotonin-related genetic polymorphisms and CCK-4-induced panic attacks with or without 5-hydroxytryptophan pretreatment in healthy volunteers. World J Biol Psychiatry 5: 149-154.
72. Maron E, Tõru I, Vasar V, Shlik J (2004c). The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. J Psychopharmacol 18: 194-199.
73. Matsushita S, Muramatsu T, Kimura M, Shirakawa O, Mita T, Nakai T et al (1997). Serotonin transporter gene regulatory region polymorphism and panic disorder. Mol Psychiatry 2: 390-392.
74. McCann UD, Morgan CM, Geraci M, Slate SO, Murphy DL, Post RM (1997). Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. Neuropsychopharmacology 17: 360-369.
75. Meltzer HY, Maes M (1994). Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man. Psychopharmacologia 114: 635-643.
76. Meltzer MD, Bastani MD, Jayathilake MS, Maes MD (1997). Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Neuropsychopharmacology 17: 1-11.
77. 2-induced anxiety in patients with panic disorder and normal volunteers. Br J Psychiatry 176: 182-188.
78. Mortimore C, Anderson IM (2000). d-Fenfluramine in panic disorder: a dual role for 5-hydroxytryptamine. Psychopharmacologia 149: 251-258.
79. Nash JR, Sargen PA, Rabiner EA, Hood SD, Argyropoulos SV, Grasby RM et al (2004). Altered 5HT1A binding in panic disorder demonstrated by positron emission tomography. Eur Neuropsychopharmacol 14(Suppl 3): 322-323.
80. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA et al (2004). Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 24: 589-591.
81. Noyes R, Crowe RR, Harris EL, Hamra BJ, McChesney CM, Chaudhry DR (1986). Relationship between panic disorder and agoraphobia. A family study. Arch Gen Psychiatry 43: 227-232.
82. Nutt DJ (1998). Antidepressants in panic disorder: clinical and preclinical mechanisms. J Clin Psychiatry 59: 24-28.
83. Nutt DJ, Forshall S, Bell C, Rich A, Sandford J, Nash J et al (1999). Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol 9(Suppl 3): 81-86.
84. Perna G, Bella D, Favaron E, Cucchi M, Liperi L, Bellodi L (2004). Lack of relationship between CO(2) reactivity and serotonin transporter gene regulatory region polymorphism in panic disorder. Am J Med Genet 129: 41-43.
85. Perna G, Bertani A, Gabriele A, Politi E, Bellodi L (1997). Modification of 35% carbon dioxide hypersensitivity across one week of treatment with clomipramine and fluvoxamine: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 17: 173-178.
86. Perna G, Favaron E, Di Bella D, Bussi R, Bellodi L (2005). Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology [Epub ahead of print].
87. Phillips RG, LeDoux JE (1992). Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106: 274-285.
88. Polesskaya OO, Sokolov BP (2002). Differential expression of the 'C' and 'T' alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 67: 812-822.
89. Pranzatelli MR, Durkin MM, Barkai AI (1994). Quantitative autoradiography of 5-hydroxytryptaminelA binding sites in rats with chronic neonatal 5,7-dihydroxytryptamine lesions. Brain Res Dev Brain Res 80: 1-6.
90. Rothe C, Gutknecht L, Freitag C, Tauber R, Mossner R, Franke P et al (2004a). Association of a functional 1019C > G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia. Int J Neuropsychopharmacol 7: 189-192.
91. Rothe C, Koszycki D, Bradwejn J, King N, De Luca V, Shaikh S et al (2004b). Association study of serotonin-2A receptor gene polymorphism and panic disorder in patients from Canada and Germany. Neurosci Lett 363: 276-279.
92. Samochowiec J, Hajduk A, Samochowiec A, Horodnicki J, Stepien G, Grzywacz A et al (2004). Association studies of MAO-A, COMT, and 5-HTT genes polymorphisms in patients with anxiety disorders of the phobic spectrum. Psychiatry Res 128: 21-26.
93. Sanghera MK, Coke JA, Williams HL, McMillen BA (1990). Ipsapirone and 1-(2-pyrimidinyl)-piperazine increase rat locus coeruleus noradrenergic activity. Brain Res Bull 24: 17-22.
94. Schmidt NB, Storey J, Greenberg BD, Santiago HT, Li Q, Murphy DL (2000). Evaluating gene x psychological risk factor effects in the pathogenesis of anxiety: a new model approach. J Abnorm Psychol 109: 308-320.
95. 2 provoked panic in panic disorder. J Psychopharmacol 18: 553-558.
96. Schruers K, Klaassen T, Pols H, Overbeek T, Deutz NE, Griez E (2000). Effects of tryptophan depletion on carbon dioxide provoked panic in panic disorder patients. Psychiatry Res 93: 179-187.
97. Schruers K, van Diest R, Overbeek T, Griez E (2002). Acute-5- hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. Psychiatry Res 113: 237-243.
98. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J (1997). Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22: 332-340.
99. Smoller JW, Tsuang MT (1998). Panic and phobic anxiety: defining phenotypes for genetic studies. Am J Psychiatry 155: 1152-1162.
100. Solyom L (1994). Controlling panic attacks with fenfluramine. Am J Psychiatry 151: 621-622.
101. Spurlock G, Buckland P, O'Donovan M, McGuffin P (1994). Lack of effect of antidepressant drugs on the levels of mRNAs encoding serotonergic receptors, synthetic enzymes and 5HT transporter. Neuropharmacology 33: 433-440.
102. Swain J, Koszycki D, Shlik J, Bradwejn J (2003). Pharmacological challenge agents in anxiety. In: Nutt DJ, Ballenger JC (eds). Anxiety Disorders. Blackwell Science: UK. pp 269-295.
103. Tadic A, Rujescu D, Szegedi A, Giegling I, Singer P, Moller HJ et al (2003). Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. Am J Med Genet 117: 1-6.
104. Talbot PS (2004). The molecular neuroimaging of anxiety disorders. Curr Psychiatry Rep 6: 274-279.
105. Targum SD, Marshall LE (1989). Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 28: 295-306.
106. Tyrer P, Shawcross C (1988). Monoamine oxidase inhibitors in anxiety disorders. J Psychiatr Res 22: 87-98.
107. van Megen HJ, Westenberg HG, den Boer JA, Slaap B, Scheepmakers A (1997). Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacologia 129: 357-364.
108. van Vliet IM, Slaap BR, Westenberg HG, Den Boer JA (1996). Behavioral, neuroendocrine and biochemical effects of different doses of 5-HTP in panic disorder. Eur Neuropsychopharmacol 6: 103-110.
109. Verge D, Daval G, Marcinkiewicz M, Patey A, Mestikawy S, Gozlan H et al (1986). Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J Neurosci 6: 3474-3482.
110. Welner SA, De Montigny C, Desroches J, Desjardins P, Suranyi-Cadotte BE (1989). Autoradiographic quantification of serotonin1A receptors in rat brain following antidepressant drug treatment. Synapse 4: 347-352.
111. Wetzler S, Asnis GM, DeLecuona JM, Kalus O (1996). Serotonin function in panic disorder: intravenous administration of meta-chlorophenylpiperazine. Psychiatry Res 64: 77-82.
112. Wu S, Comings DE (1999). A common C-1018G polymorphism in the human 5-HT1A receptor gene. Psychiatr Genet 9: 105-106.
113. Young SN, Smith SE, Pihl RO, Ervin FR (1985). Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacologia 87: 173-177.
114. Zhang X, Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG (2004). Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 305: 217.